Figure 1.
A flow chart of the experimental design.
Table 1.
Demographic and clinical features of NAFLD patients and healthy controls in the screening set.
Table 2.
Demographic and clinical features of NAFLD patients and healthy controls in the training set.
Table 3.
Demographic and clinical features of the NAFLD patients and healthy controls in the validation set.
Figure 2.
Sequenced reads and distribution of reads.
The Illumina GA IIx sequencing of the small RNA library from the serum of healthy controls and NAFLD patients produced 906,910 and 944,362 raw-reads, respectively. After extensive preprocessing and quality control, these raw reads were reduced to 494,523 and 462,263 clean reads, indicating 54.53% and 48.95% of sequenced reads (Figs. 2A, 2B). The entire distribution of reads from 16 to 30 nt is presented in Fig. 2C.
Table 4.
Differentially expressed miRNAs between CTL and NAFLD.
Figure 3.
Relative expression of miRNAs between controls and NAFLD patients.
Relative expression of 6 candidate miRNAs between controls and NAFLD patients in the training set.
Figure 4.
AUC of miRNAs between controls and NAFLD patients.
Area under the curve (AUC) of miRNAs. A: miRNA-122; B: miRNA-1290; C: miRNA-27b-3p; D: miRNA-192-5p; E: miRNA-148a-3p; and F: miRNA-99a-5p.
Table 5.
MicroRNA profile and diagnostic performance in training dataset.
Figure 5.
AUC of miRNA panel in the training set and validation set.
A: AUC for the miRNA panel in the training set and B: AUC of the miRNA panel in the validation set.
Table 6.
Logistic regression of miRNAs and miRNAs panel in training dataset.
Figure 6.
AUC of the miRNA panel in different NAS stages.
The corresponding AUCs for patients with NAS stages <3 (A), ≥3 <5 (B), and ≥5 (C) were 0.826, 0.937, and 0.860, respectively.
Figure 7.
A: Comparison curves of ROC between ALT and miRNA panel in the validation set; B: Comparison curves of ROC between each miRNA and miRNA panel in the validation set.
Figure 8.
AUC of the FIB-4 and compared with miRNA panel.
A: AUC for the FIB-4 in the validation set and B: Comparison curves of ROC with miRNA panel.